keyword
MENU ▼
Read by QxMD icon Read
search

immunoediting

keyword
https://www.readbyqxmd.com/read/28275390/dual-role-of-inflammatory-mediators-in-cancer
#1
REVIEW
T G Shrihari
Inflammation is the body's response to noxious stimuli such as infectious, physiological or chemical agents, it releases various inflammatory mediators via immune cells such as neutrophils, macrophages, and lymphocytes. These inflammatory mediators are growth factors, chemokines, and cytokines. Reactive oxygen species (ROS) and nitrogen species (RNS) activate transcriptional factors (NF-KB, STAT-3) and bring about cellular proliferation, genomic instability, angiogenesis, resistance to apoptosis, invasion, and metastasis...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28256642/identifying-the-optimal-anticancer-targets-from-the-landscape-of-a-cancer-immunity-interaction-network
#2
Chunhe Li
Cancer immunotherapy, an approach of targeting immune cells to attack tumor cells, has been suggested to be a promising way for cancer treatment recently. However, the successful application of this approach warrants a deeper understanding of the intricate interplay between cancer cells and the immune system. Especially, the mechanisms of immunotherapy remain elusive. In this work, we constructed a cancer-immunity interplay network by incorporating interactions among cancer cells and some representative immune cells, and uncovered the potential landscape of the cancer-immunity network...
March 3, 2017: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/28212890/annexin-a1-influences-in-breast-cancer-controversies-on-contributions-to-tumour-host-and-immunoediting-processes
#3
REVIEW
Yan Tu, Cameron N Johnstone, Alastair G Stewart
Annexin A1 is a multifunctional protein characterised by its actions in modulating the innate and adaptive immune response. Accumulating evidence of altered annexin A1 expression in many human tumours raises interest in its functional role in cancer biology. In breast cancer, altered annexin A1 expression levels suggest a potential influence on tumorigenic and metastatic processes. However, reports of conflicting results reveal a relationship that is much more complex than first conceptualised. In this review, we explore the diverse actions of annexin A1 on breast tumour cells and various host cell types, including stromal immune and structural cells, particularly in the context of cancer immunoediting...
February 14, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28176650/is-there-a-role-for-epigenetic-enhancement-of-immunomodulatory-approaches-to-cancer-treatment
#4
Kirsty J Flower, Sadaf Ghaem-Maghami, Robert Brown
The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with positive clinical trials showing durable responses, attention must be paid to the subset of patients that do not respond to these treatments. Immune surveillance and immunoediting by the host could itself select for immune-evasive tumour cells during tumour development leading to immunotherapy resistance...
February 5, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28100240/reactivation-of-dormant-anti-tumor-immunity-a-clinical-perspective-of-therapeutic-immune-checkpoint-modulation
#5
REVIEW
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer
In favor of their outgrowth, cancer cells must resist immune surveillance and edit the immune response. Cancer immunoediting is characterized by fundamental changes in the cellular composition and the inflammatory cytokine profiles in the microenvironment of the primary tumor and metastatic niches, with an ever increasing complexity of interactions between tumor cells and the immune system. Recent data suggest that genetic instability and immunoediting are not necessarily disparate processes. Increasing mutational load may be associated with multiple neoepitopes expressed by the tumor cells and thus increased chances for the immune system to recognize and combat these cells...
January 19, 2017: Cell Communication and Signaling: CCS
https://www.readbyqxmd.com/read/28031719/potential-role-of-immunotherapy-in-advanced-non-small-cell-lung-cancer
#6
REVIEW
Ramon Andrade de Mello, Ana Flávia Veloso, Paulo Esrom Catarina, Sara Nadine, Georgios Antoniou
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27995176/epithelial-ovarian-cancer-inherent-resistance-may-the-pleiotropic-interaction-between-reduced-immunosurveillance-and-drug-resistant-cells-play-a-key-role
#7
Antonio Simone Laganà, Vincenza Sofo, Salvatore Giovanni Vitale, Onofrio Triolo
•Cancer cells may have inherent chemoresistance which allows an indefinite expansion.•Transformed ovarian epithelial cells may undergo an immunoediting process.•Immunoedited ovarian cancer drug-resistant cells escape first-line chemotherapy.
November 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27880900/tailored-tumor-immunogenicity-reveals-regulation-of-cd4-and-cd8%C3%A2-t-cell-responses-against-cancer
#8
Sarah Knocke, Bettina Fleischmann-Mundt, Michael Saborowski, Michael P Manns, Florian Kühnel, Thomas C Wirth, Norman Woller
CD4 and CD8 T cells play a pivotal role in controlling tumor growth. However, the interplay of both cell types and their role in tumor suppression still remain elusive. In this study, we investigated the regulation of CD4 and CD8 T cell responses to different classes of tumor-specific antigens in liver cancer mouse models. Tumors were induced in p19Arf-deficient mice by hydrodynamic injection of transposon plasmids encoding NrasG12V and pre-defined tumor antigens. This allowed for assessing the regulation of tumor-specific CD4 and CD8 T cell responses...
November 22, 2016: Cell Reports
https://www.readbyqxmd.com/read/27843441/the-janus-face-of-death-receptor-signaling-during-tumor-immunoediting
#9
REVIEW
Eimear O' Reilly, Andrea Tirincsi, Susan E Logue, Eva Szegezdi
Cancer immune surveillance is essential for the inhibition of carcinogenesis. Malignantly transformed cells can be recognized by both the innate and adaptive immune systems through different mechanisms. Immune effector cells induce extrinsic cell death in the identified tumor cells by expressing death ligand cytokines of the tumor necrosis factor ligand family. However, some tumor cells can escape immune elimination and progress. Acquisition of resistance to the death ligand-induced apoptotic pathway can be obtained through cleavage of effector cell expressed death ligands into a poorly active form, mutations or silencing of the death receptors, or overexpression of decoy receptors and pro-survival proteins...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27764780/the-concept-of-immune-surveillance-against-tumors-the-first-theories
#10
REVIEW
Domenico Ribatti
The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system...
January 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/27751760/neoantigens-in-immunotherapy-and-personalized-vaccines-implications-for-head-and-neck-squamous-cell-carcinoma
#11
Paul Zolkind, Gavin P Dunn, Tianxiang Lin, Malachi Griffith, Obi L Griffith, Ravindra Uppaluri
The recent success of immunotherapies has demonstrated the potency of tumor-specific immune cells in mediating tumor rejection and generating durable tumor immunity. Our understanding of the scientific basis of these responses results from the confluence of a better comprehension of the cancer immunoediting process and the revolution in next generation sequencing of cancer genomes. Recent evidence suggests that T cell specificity for cancer cell expressed mutant proteins - termed neoantigens - is an important component of immune mediated tumor rejection...
October 14, 2016: Oral Oncology
https://www.readbyqxmd.com/read/27642636/lack-of-immunoediting-in-murine-pancreatic-cancer-reversed-with-neoantigen
#12
Rebecca A Evans, Mark S Diamond, Andrew J Rech, Timothy Chao, Max W Richardson, Jeffrey H Lin, David L Bajor, Katelyn T Byrne, Ben Z Stanger, James L Riley, Nune Markosyan, Rafael Winograd, Robert H Vonderheide
In carcinogen-driven cancers, a high mutational burden results in neoepitopes that can be recognized immunologically. Such carcinogen-induced tumors may evade this immune response through "immunoediting," whereby tumors adapt to immune pressure and escape T cell-mediated killing. Many tumors lack a high neoepitope burden, and it remains unclear whether immunoediting occurs in such cases. Here, we evaluated T cell immunity in an autochthonous mouse model of pancreatic cancer and found a low mutational burden, absence of predicted neoepitopes derived from tumor mutations, and resistance to checkpoint immunotherapy...
September 8, 2016: JCI Insight
https://www.readbyqxmd.com/read/27605070/restoring-anti-oncodriver-th1-responses-with-dendritic-cell-vaccines-in-her2-neu-positive-breast-cancer-progress-and-potential
#13
Lucy M De La Cruz, Nadia F Nocera, Brian J Czerniecki
HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 response can predict response to neoadjuvant therapy, risk of recurrence and disease-free survival. Vaccines consisting of HER2-pulsed type I polarized dendritic cells (DC1) administered during ductal carcinoma in situ and early IBC can efficiently correct anti-HER2Th1 response and have clinical impact on the disease...
October 2016: Immunotherapy
https://www.readbyqxmd.com/read/27603507/role-of-tregs-in-cancer-dormancy-or-recurrence
#14
REVIEW
Masoud H Manjili, Savannah E Butler
The immunogenic tumor dormancy has been demonstrated in animal models of cancer, which can explain clinical observations such as an increased incidence of cancer following organ transplantation. The role of immune cell populations in the maintenance of, or escape from, tumor dormancy and subsequent recurrence is poorly understood. Here, we provide a review of literature related to the contribution of Tregs in tumor dormancy or recurrence. Based on clinical results, we suggest that anecdotal reports on the association of human Tregs with poor prognosis are circumstantial rather than implying a cause-effect direction...
November 2016: Immunological Investigations
https://www.readbyqxmd.com/read/27553942/telltale-tumor-infiltrating-lymphocytes-til-in-oral-head-neck-cancer
#15
Yu Lei, Yuying Xie, Yee Sun Tan, Mark E Prince, Jeffrey S Moyer, Jacques Nör, Gregory T Wolf
Evidence gleaned from recent studies on the role of tumor-infiltrating lymphocytes (TILs) suggests that cancer is not only a genetic disease but also an immunologic disease. Head and Neck Squamous Cell Carcinoma (HNSCC) has been a significant model to study cancer cell-immune cell interactions. First, immune cell infiltration is an important feature of these tumors. Second, HNSCC frequently develops resistance to immunogenic cytotoxicity, which provides a window to decipher how tumors engage the immune system to establish immune tolerance...
October 2016: Oral Oncology
https://www.readbyqxmd.com/read/27441558/the-immune-landscapes-of-polypoid-and-nonpolypoid-precancerous-colorectal-lesions
#16
Antonella Maglietta, Rosalia Maglietta, Teresa Staiano, Ramona Bertoni, Nicola Ancona, Giancarlo Marra, Leonardo Resta
Little is known about the immunoediting process in precancerous lesions. We explored this aspect of benign colorectal adenomas with a descriptive analysis of the immune pathways and immune cells whose regulation is linked to the morphology and size of these lesions. Two series of polypoid and nonpolypoid colorectal adenomas were used in this study: 1) 84 samples (42 lesions, each with matched samples of normal mucosa) whose gene expression data were used to quantify the tumor morphology- and size-related dysregulation of immune pathways collected in the Molecular Signature Database, using Gene Set Enrichment Analysis; 2) 40 other lesions examined with immunohistochemistry to quantify the presence of immune cells in the stromal compartment...
2016: PloS One
https://www.readbyqxmd.com/read/27441513/update-on-new-therapies-with-immune-checkpoint-inhibitors
#17
Jennifer J Peterson, Susan K Steele-Moses
BACKGROUND: Immunotherapy has had a long history in cancer treatment and, with recent breakthroughs, new drugs are available that have shown promising results. OBJECTIVES: The current article discusses an overview of immune function, including immunoediting and the theory of immune checkpoints, as well as specific drugs that have been approved as immune checkpoint inhibitors. Additional discussion includes a review of nursing implications and administration, side effects, adverse events, and the future of immuno-oncology...
August 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27435394/follicle-stimulating-hormone-receptor-is-expressed-by-most-ovarian-cancer-subtypes-and-is-a-safe-and-effective-immunotherapeutic-target
#18
Alfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R Rutkowski, Michael J Allegrezza, Amelia J Tesone, Kyle K Payne, Jayamanna Wickramasinghe, Jenny M Nguyen, Shane W O'Brien, Kiranmai Gumireddy, Qihong Huang, Mark G Cadungog, Denise C Connolly, Julia Tchou, Tyler J Curiel, Jose R Conejo-Garcia
PURPOSE: To define the safety and effectiveness of T cells redirected against follicle-stimulating hormone receptor (FSHR)-expressing ovarian cancer cells. EXPERIMENTAL DESIGN: FSHR expression was determined by Western blotting, immunohistochemistry, and qPCR in 77 human ovarian cancer specimens from 6 different histologic subtypes and 20 human healthy tissues. The effectiveness of human T cells targeted with full-length FSH in vivo was determined against a panel of patient-derived xenografts...
January 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27411023/recent-advances-and-future-of-immunotherapy-for-glioblastoma
#19
Neha Kamran, Alexandra Calinescu, Marianela Candolfi, Mayuri Chandran, Yohei Mineharu, Antonela S Asad, Carl Koschmann, Felipe J Nunez, Pedro R Lowenstein, Maria G Castro
INTRODUCTION: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. AREAS COVERED: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients...
October 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27350335/neoantigen-landscape-dynamics-during-human-melanoma-t-cell-interactions
#20
Els M E Verdegaal, Noel F C C de Miranda, Marten Visser, Tom Harryvan, Marit M van Buuren, Rikke S Andersen, Sine R Hadrup, Caroline E van der Minne, Remko Schotte, Hergen Spits, John B A G Haanen, Ellen H W Kapiteijn, Ton N Schumacher, Sjoerd H van der Burg
Recognition of neoantigens that are formed as a consequence of DNA damage is likely to form a major driving force behind the clinical activity of cancer immunotherapies such as T-cell checkpoint blockade and adoptive T-cell therapy. Therefore, strategies to selectively enhance T-cell reactivity against genetically defined neoantigens are currently under development. In mouse models, T-cell pressure can sculpt the antigenicity of tumours, resulting in the emergence of tumours that lack defined mutant antigens...
August 4, 2016: Nature
keyword
keyword
102772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"